article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Pharma R&D teams are solving this problem by leveraging the power of artificial intelligence (AI) in clinical trials to save time and money.

article thumbnail

Clinical Trials for Pulmonary Fibrosis: How Can Participation Be Improved?

XTalks

Clinical trials for pulmonary fibrosis are being conducted to evaluate the effectiveness of novel therapies and interventions, providing hope for improved outcomes in the future. Anti-fibrotic therapies: Anti-fibrotic drugs have shown promise in treating pulmonary fibrosis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diversity in Clinical Trials: Tackling the Issues in Alzheimer’s Research at AAIC 2021

XTalks

Just as clinical researchers in other therapeutic areas have renewed their commitment to improving participant diversity in clinical trials, so too have those working in Alzheimer’s research. Fortunately, there are a number of researchers working on this issue.

article thumbnail

AI-discovered ALS drug trial uses unique remote monitoring

Drug Discovery World

VRG50635 is a small molecule PIKfyve inhibitor and is reportedly one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW).

article thumbnail

Integration of AI in imaging clinical trials 

Drug Discovery World

Sophie Winandy , Executive Director of Medical Imaging at ICON explores the benefits of AI and how it can be integrated throughout medical imaging within clinical trials. These advances are seen in many indications of imaging as it relates to drug trials – oncological, cardiovascular, metabolic, NASH, musculoskeletal and other.

article thumbnail

Scleroderma drug trial shows up to 60% improvement

Drug Discovery World

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.

article thumbnail

New lupus partnership with FDA aims to end drug trials’ history of failure

STAT News

Lupus is a disease long-plagued by failed clinical trials. And hopeful patients, many of them young women of color, are waiting — just three lupus drugs have been approved by the Food and Drug Administration in six decades. A key partnership is looking to change that.